Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy

Ziyu Wei, Yu Yi, Zhen Luo, Xiaoyun Gong, Yuxing Jiang, Dayong Hou, Li Zhang, Zimo Liu, Mandi Wang, Jie Wang, Ruochen Guo, Jinjun Yang, Lei Wang, Hao Wang, Yuliang Zhao

Research output: Contribution to journalArticlepeer-review

Abstract

Chemoimmunotherapy using nanotechnology has shown great potential for cancer therapy in the clinic. However, uncontrolled transportation and synergistic responses remain challenges. Here, a self-assembled selenopeptide nanoparticle that strengthens tumor chemoimmunotherapy through the activation of natural killer (NK) cells by the oxidative metabolite of the selenopeptide is developed. With the advantages of the enzyme-induced size-reduction and the reactive-oxygen-species-driven deselenization, this selenopeptide is able to deliver therapeutics, e.g., doxorubicin (DOX), to solid tumors and further activate the NK cells in a programmed manner. Importantly, in vitro and in vivo results prove the mutual promotion between the DOX-induced chemotherapy and the selenopeptide-induced immunotherapy, which synergistically contribute to the improved antitumor efficacy. It is anticipated that the selenopeptide may provide a type of promising stimuli-responsive immune modulator for versatile biomedical applications.

Original languageEnglish (US)
Article number2108167
JournalAdvanced Materials
Volume34
Issue number17
DOIs
StatePublished - Apr 27 2022

Keywords

  • chemoimmunotherapy
  • drug delivery
  • programmable nanomedicine
  • selenopeptide
  • self-assembly

ASJC Scopus subject areas

  • Materials Science(all)
  • Mechanics of Materials
  • Mechanical Engineering

Fingerprint

Dive into the research topics of 'Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy'. Together they form a unique fingerprint.

Cite this